Home About Epidemiology Team Work Pricing Contact Us
Logo

Diagnose wIth ArtficiaL IntelliGence in hEad and Neck Cancer rElapses

DILIGENCE

HNSCC is know to be difficult for the practice of conventional biopsy. That’s why our team named DILIGENCE thought about an innovative biopsy less painful and less invasive which is the liquid biopsy.

Our objective is to act as quickly as possible before relapses or second primary tumors which are really common and explained the poor prognosis. Secondly, we want to ensure a precision follow-up for each patient. We want to provide an early diagnosis of HNSCC with the help of liquid biopsy kits analyzed by a machine incorporating AI which precisely give prognostics of the risk of recurrence thanks to clinical and NGS data. This will be focus on genes panel known to be altered in HNSCC. This will allow to reduce coast and be more effective for the Public Health and Hospital

HNSCC Epidemiology

In France Prevalence (green): 34,930 patients with a diagnosis of HNSCC which need follow-up Incidence (blue): 11340 newly diagnosed cases per year which will require follow-up Mortality (red): 2730 death per year

Age Cases Age I

THE TEAM

The ones who runs this company

Jebrane

Jebrane Bouaoud

PhD1 (MD Maxillofacial Surgeon)

Head and neck oncology, Genomic/Immune dynamic of Head and neck carcinogenesis, Management and Communication

Jane

Marta Alonso Pelaez

Management & Innovation in HealthCare technologies

Medical Imaging, Programming and Management

Mike

Claire Coquet

Cancerology

Physiology, Oncology and Epigenetics

Candice

Candice Wolf

Cancerology

Cancer Studies

Yassmine

Yassmine El Yandouzi

Cancerology

Physiology, Cancerology and histology

Yajing

Yajing Zhao

Healthy Living Technologies

Physiology, Pathology & Pharmacy management

Lixiang

Lixiang Qian

Healthy Living Technologies

Physiology, Pathology & Pharmacy management

Pranav

Pranav Swaroop

Bioinformatics

Data Science, Bioinformatics, Web Designing & Programming

1+
Potential Competitors
5+
Interviews Done
20+
Meetings
1000+
Happy Patients

Our Proposal.

  • We want to change this paradox/ this standard follow-up
  • Adapt follow-up to patients in order to reassure patients at low-risk, while precisely identifying those at risk in order to make earlier diagnoses and propose them less morbid curative treatment.
  • This strategy of “risk precision” will allow the doctor/hospitals to be more efficient and society to save money.

Genes Identification on Panel

100%

Analysis

85%

Results

100%

PRICING

Choose a pricing plan that fits your needs.

  • Basic
  • 10Samples Testing
  • 10 Emails
  • 10 Reports
  • Endless Support

  • € 10

    per month
  • Pro
  • 25Samples Testing
  • 25 Emails
  • 25 Reports
  • Endless Support

  • € 25

    per month
  • Premium
  • 50Samples Testing
  • 50 Emails
  • 50 Reports
  • Endless Support

  • € 50

    per month

Pricing is still under progress....

CONTACT

Lets get in touch. Send us a message:

Lyon, FR

Phone: +33 15150015

Email: docorp@diligence.com


"Live life."

Supported By: